Trials / Completed
CompletedNCT04602221
A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
A Randomized, Placebo Controlled, Double-blind, Double-dummy Three-way Cross Over Trial to Investigate the Effect of BI 409306, BI 425809 and Lamotrigine on Ketamine-induced Cognitive Deficits in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this trail is to investigate if and to what extent BI 409306, BI 425809 and lamotrigine attenuate ketamine induced cognitive deficits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lamotrigine | Tablet |
| DRUG | BI 409306 | Film-coated tablet |
| DRUG | Placebo | Tablet, Film-coated tablet |
| DRUG | BI 425809 | Film-coated tablet |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2022-08-01
- Completion
- 2022-08-12
- First posted
- 2020-10-26
- Last updated
- 2024-03-12
- Results posted
- 2024-03-12
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04602221. Inclusion in this directory is not an endorsement.